Study of Misoprostol to Improve Cervical Cancer Prevention in Women with Type 3 Transformation Zone

What this Trial Is About

Researchers are evaluating the use of Misoprostol to improve cervical cancer prevention in non-pregnant women who are undergoing cancer screening with visual inspection using acetic acid VIA. This trial focuses on women with a Type 3 transformation zone TZ and compares the effects of Misoprostol versus a placebo. The study is a double-blind randomized controlled trial involving 420 participants. Participants will be randomly assigned to receive either 600 mcg of Misoprostol 3 tablets or an identical placebo, both administered vaginally. The medication is given twice once 2-3 hours before VIA and again 4-6 hours prior. The study aims to observe the conversion rate from Type 3 TZ to Types 1 or 2 TZ at these two time points. During the trial, women will undergo VIA screening after receiving the study medication. Researchers will measure the rate at which the transformation zone changes type and compare the results between the two time windows after drug administration. The primary outcome is the conversion rate from Type 3 to Types 1 or 2 TZ. Secondary outcomes include comparing conversion rates between the two different timing intervals. The trial is expected to conclude by November 2027.

Use Misoprostol to Optimize Prevention of Cervical Cancer